10 Most Profitable European Stocks To Invest In

3. AstraZeneca PLC (NASDAQ:AZN)

Upside Potential: 36.94%

5-Year Net Income CAGR: 25.87%

TTM Net Income: $6.49 Billion 

AstraZeneca PLC (NASDAQ:AZN) is a leading biopharmaceutical company that develops, manufactures, and sells prescription medicines for various medical conditions. Three of the company’s top therapeutic areas are oncology, cardiovascular, renal, and metabolism (CVRM), and respiratory and immunology.

AstraZeneca PLC’s (NASDAQ:AZN) competitive advantage lies around its innovation pipeline and rising demand for its current treatments. Tagrisso, Imfinzi, and Calquence are all key to increasing sales of the company and the oncology therapy division is a major growth engine. The company’s steady sales of Symbicort and the rapid growth in Farxiga volume have boosted the CVRM therapeutic division. Whereas, the company’s rare disease therapeutic division is expanding based on increasing sales of Ultomiris and Soliris.

In Q3, the company’s total revenue increased by 21% year-over-year to $13.57 billion and the core EPS soared 27% to $2.08. Over the past nine months, AstraZeneca’s revenue has increased 19%, which shows the company’s solid performance.

The company is heavily focused on growth in the U.S. and that is why it is investing almost $3.5 billion in manufacturing and R&D in New York. AstraZeneca PLC (NASDAQ:AZN) remains one of the most promising stocks in the healthcare sector.